Bleeding disorders
Follow the links below to find trusted information about bleeding disorders.
Last reviewed: July 2016
Need more information?
These trusted information partners have more on this topic.
Found 1399 results
HIV and Bleeding Disorders - Haemophilia Foundation Australia
An introduction to information on haemophilia, von Willebrand Disorder and related bleeding disorders and related information on hepatitis C and HIV.
Read more on Haemophilia Foundation Australia website
Women with Bleeding Disorders - Haemophilia Foundation Australia
An introduction to information on haemophilia, von Willebrand Disorder and related bleeding disorders and related information on hepatitis C and HIV.
Read more on Haemophilia Foundation Australia website
Bleeding disorders - Lab Tests Online AU
A bleeding disorder is an acquired or inherited tendency to bleed excessively. Normally, blood remains in the circulatory system inside the blood vessels. However, if veins or arteries are injured, they will begin to leak blood, either externally or into body tissues. The body stops the blood loss through a complex clotting process called haemostasis. During haemostasis, the injured blood vessel constricts to reduce blood flow, platelets adhere to the injury site and clump together to form a loose platelet plug, and a process of clot formation called the coagulation cascade is initiated.
Read more on Lab Tests Online website
Haemophilia: what is it? - myDr.com.au
Haemophilia is an inherited bleeding disorder where the blood doesn't clot properly.
Read more on myDr website
View All FAQs - Haemophilia Foundation Australia
An introduction to information on haemophilia, von Willebrand Disorder and related bleeding disorders and related information on hepatitis C and HIV.
Read more on Haemophilia Foundation Australia website
Factor XI Deficiency - Haemophilia Foundation Australia
An introduction to information on haemophilia, von Willebrand Disorder and related bleeding disorders and related information on hepatitis C and HIV.
Read more on Haemophilia Foundation Australia website
Hepatitis C - Haemophilia Foundation Australia
An introduction to information on haemophilia, von Willebrand Disorder and related bleeding disorders and related information on hepatitis C and HIV.
Read more on Haemophilia Foundation Australia website
Telling Others - Haemophilia Foundation Australia
An introduction to information on haemophilia, von Willebrand Disorder and related bleeding disorders and related information on hepatitis C and HIV.
Read more on Haemophilia Foundation Australia website
Factor X Deficiency - Haemophilia Foundation Australia
An introduction to information on haemophilia, von Willebrand Disorder and related bleeding disorders and related information on hepatitis C and HIV.
Read more on Haemophilia Foundation Australia website
Factor VII Deficiency - Haemophilia Foundation Australia
An introduction to information on haemophilia, von Willebrand Disorder and related bleeding disorders and related information on hepatitis C and HIV.
Read more on Haemophilia Foundation Australia website
Found 181 results
Preventing bleeding in people with congenital bleeding disorders during and after surgery | Cochrane
In haemophilia and other congenital bleeding disorders blood does not clot properly, which can cause excessive bleeding. This is particularly relevant during surgery, when the risk of bleeding depends on the type and severity of the clotting disorder and on the type of surgery. Therefore, during and after surgery, these individuals should receive treatment to improve the ability of their blood to clot and so prevent bleeding. Clotting factor concentrates (when available and appropriate in those individuals missing specific clotting proteins) or other non-specific drugs for clotting, or a combination of both, are administered. It is not known what is the optimal dose or duration or method of administration of these treatments in these circumstances.
Read more on Cochrane (Australasian Centre) website
Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders | Cochrane
Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders
Read more on Cochrane (Australasian Centre) website
Medical therapies for treating heavy menstrual bleeding in women with bleeding disorders | Cochrane
Read more on Cochrane (Australasian Centre) website
Mother and baby outcomes following normal delivery and caesarean (c-section) delivery in women with bleeding disorders and carriers | Cochrane
Mother and baby outcomes following normal delivery and caesarean (c-section) delivery in women with bleeding disorders and carriers
Read more on Cochrane (Australasian Centre) website
Use of desmopressin to reduce the need for blood transfusions in patients who do not suffer from congenital bleeding disorders. | Cochrane
Use of desmopressin to reduce the need for blood transfusions in patients who do not suffer from congenital bleeding disorders.
Read more on Cochrane (Australasian Centre) website
Treatments for acute bleeds in people with acquired hemophilia A | Cochrane
Acquired hemophilia A is a rare but severe bleeding disorder caused by the autoantibody directed against factor VIII (FVIII, a blood clotting protein) in patients with no previous history of a bleeding disorder. This bleeding disorder occurs more frequently in the elderly and may be associated with several other conditions, such as solid tumours, autoimmune diseases, or with drugs; it is also sometimes associated with pregnancy. However, in about half of the cases the causes are unknown. Bleeding occurs in the skin; mucous membranes; and muscles; with joint bleeds being unusual. Therapies for acquired hemophilia A include treatments to stop acute bleeds and to destroy the FVIII autoantibodies. Acute bleeds can be treated with recombinant activated FVII or activated prothrombin complex concentrate (aPCC). If these are unavailable, FVIII concentrates or 1-desamino-8-D-arginine-vasopressin (DDAVP) fresh frozen plasma can be attempted; however, these last two options are not usually effective, and it is not known if one of these products is better than the other.
Read more on Cochrane (Australasian Centre) website
TEG and ROTEM for diagnosing traumainduced coagulopathy (disorder of the clotting system) in adult trauma patients with bleeding | Cochrane
TEG and ROTEM for diagnosing traumainduced coagulopathy (disorder of the clotting system) in adult trauma patients with bleeding
Read more on Cochrane (Australasian Centre) website
Rituximab for eradicating inhibitors in people with acquired haemophilia A | Cochrane
We reviewed the evidence about the effect of rituximab for treating people with acquired haemophilia A.
Read more on Cochrane (Australasian Centre) website
Drugs that prevent oral bleeding in people with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions | Cochrane
Drugs that prevent oral bleeding in people with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions
Read more on Cochrane (Australasian Centre) website
Synthetic surfactant for respiratory distress syndrome in preterm infants | Cochrane
Synthetic surfactant is effective in reducing respiratory distress syndrome in preterm babies. Pulmonary surfactant is a substance that prevents the air sacs of the lungs from collapsing by reducing surface tension. Sometimes it is absent in immature lungs and respiratory distress syndrome (RDS) can develop. Synthetic surfactants have been developed and can be used for babies born prematurely (before 34 weeks) who have RDS. The review of trials found evidence that synthetic surfactant for babies with RDS is effective. Synthetic surfactant reduced the risk of pneumothorax (air in the lung cavity) and death. The only adverse effect is the increased risk of pulmonary hemorrhage (bleeding in the lungs), seen with the use of either synthetic or natural surfactant.
Read more on Cochrane (Australasian Centre) website
